IKOULA
9.12.2021 10:02:06 CET | Business Wire | Press release
The French specialist in web hosting, dedicated servers and cloud computing IKOULA announced a joint case study with the leading open-source cloud management software CloudStack. For the management of their cloud environment, IKOULA decided to choose the open-source way by combining the power of CloudStack with the simplicity of the open-source hypervisor XCP-ng. Тhe turnkey combination was carefully selected following the long-term company strategy to guarantee a constant product evolution, reliability and simplicity for their customers. As a result, IKOULA is now among the most innovative cloud and managed services providers in Europe, with an extensive portfolio of cloud solutions. Moreover, a large number of customers use their CloudStack-orchestrated infrastructure to deploy memory-oriented and storage-oriented VMs or Kubernetes clusters.
The cloud and hosting market is one of the most competitive in the tech industry. Companies need to constantly innovate, be creative, offer exceptional service quality and support while keeping a competitive price. Choosing an open-source technology stack is a strategic decision taken by IKOULA. They eliminate all vendor lock-ins and ensure the company has full control over their infrastructure by being open-source. Other significant benefits are the easy management of extensive infrastructure, guaranteed reliability, and seamless scalability.
“It is essential for us as a hosting company to know exactly what is running on our servers. This is a decisive advantage in terms of security.
We decided to go with open-source solutions, as they deliver the reliability and flexibility we need. When it comes to debugging issues, we can quickly look in the code and fix it or ask the community for help on the error. CloudStack and XCP-ng have an active and growing community and constantly evolving products, which is a huge benefit”, said Joaquim Dos Santos, R&D Director at Ikoula.
CloudStack and XCP-ng also give a financial advantage to IKOULA, which is extremely important in their market segment. According to their team, operating XCP-ng and CloudStack results in greatly reduced costs than other solutions. They have also greatly reduced their reliance on 3rd parties to help maintain their environment.
At this stage, IKOULA manages a large CloudStack environment with 100+ hosts in 8 different zones and 6600+ customers using it. They can make live updates and upgrades of the system without any service interruptions for the end-users. Among the most valuable CloudStack features for them are the multi-tenancy of the solution, its scalability and the power to easily manage hundreds of hosts and thousands of VMs.
About IKOULA
Pioneer of the French Cloud since 1998, IKOULA has its own Datacenters in France, as well as two subsidiaries, in Spain and in the Netherlands. Because people are part of its DNA, IKOULA maintains a close relationship with its customers, and provides them with teams of experts available 24/7, to advise and support them in their activities. IKOULA's teams are also multilingual, in order to respond to the internationalization issues of all of its customers, located in more than 60 countries on 4 continents. Since September 2021, IKOULA has joined of the SEWAN Group.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005028/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release
Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom